• Ghosh M

Tuberculosis is aerosol generated infectious disease caused by Mycobacterium tuberculosis and its treatment remains challenging. Improved treatment strategies are needed to address the problem and to achieve the millennium target of disease elimination. Host-target therapies are a promising approach to tuberculosis treatment and have the potential to reduce the treatment duration and capability of modulation of host immune responses to reduce lung injury by enhancing autophagy, innate immune responses as well as by modifying specific host immune pathway reducing lung inflammation and matrix destruction. Persistent efforts have increased our understanding in the area of host-pathogen interaction and immune responses and it is now thought that the introduction of host targeted drugs can improve the current TB regimen and may lead to shorter treatment time, reduce in lung inflammation and lower risk of development of drug resistance or re-infection. Several options for host-directed therapies are being explored and are being discussed here for better clinical outcomes.

Mycobacterium tuberculosis; host-pathogen interaction; inflammation; drug-susceptibility

"Tuberculosis treatment strategies using ‘host directed’ therapeutics: Can we win the war ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 1, page no.1278-1283, January 2019, Available :http://www.jetir.org/papers/JETIRDY06207.pdf

"Tuberculosis treatment strategies using ‘host directed’ therapeutics: Can we win the war ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 1, page no. pp1278-1283, January 2019, Available at : http://www.jetir.org/papers/JETIRDY06207.pdf